Antonio O. M.
- Country
- Spain
- Department
- Gastroenterology Hepatology
Research Overview
- N1T-MC-MALO: A Master Protocol for a Randomized, Controlled, Clinical Trial of Multiple Pharmacologic Agents in Adult Participants With Metabolic Dysfunction-Associated Steatotic Liver Disease Who Are at Increased Risk of Developing Major Adverse Liver Outcomes (SYNERGY-Outcomes); N1T-MC-TZ01 Tirzepatide in participants with high-risk MASLD; N1T-MC-RT01 Retatrutide in participants with high-risk MASLD
- Phase III Randomized Double‑Blind Placebo‑Controlled Study of Oral Elafibranor 120 mg in Adults with Primary Sclerosing Cholangitis
- A Phase IIa, Randomized, Double-blind, Placebo-controlled Study to Evaluate Safety, Tolerability, and Pharmacodynamics of AZD4831 in Participants with Non-cirrhotic Non-alcoholic Steatohepatitis (NASH) with Fibrosis
Data & Insights
Has run more than one trial at 88 of 232 partner sites.
Specializations
Liver Disease Management
This investigator specializes in treating Primary Biliary Cholangitis (PBC) and Primary Sclerosing Cholangitis (PSC), focusing on innovative therapeutic approaches for chronic cholestatic liver conditions.
- Cholestatic Liver Diseases
- Biliary Tract Disorders
- Hepatic Function Assessment
Metabolic Liver Disorders
The investigator has extensive experience in treating Non-alcoholic Steatohepatitis (NASH) and its complications, including advanced fibrosis and cirrhosis. Their work extends to Metabolic Dysfunction-Associated Steatohepatitis.
- Liver Fibrosis
- Hepatic Fat Content Management
- Cirrhosis Care
Metabolic Health
The investigator addresses obesity-related liver conditions and their metabolic complications. Their expertise includes the management of Wilson disease and other metabolic disorders affecting hepatic function.
- Weight Management
- Metabolic Syndrome
- Copper Metabolism Disorders
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.